What is the role of adjuvant immunotherapy in contemporary melanoma care?
Adjuvant immunotherapy is still actual despite heterogeneity on its accessibility in Europe and fast advances in neoadjuvant immunotherapy
EMA Recommends Extension of Indications for Pirtobrutinib
New indication concerns the treatment of patients with relapsed or refractory chronic lymphocytic leukaemia
Fundació Catalunya La Pedrera - VHIO MD-PhD fellowship program, Vall d’Hebron Institute of Oncology, Barcelona, Spain
Application deadline: 14 May 2025